FDA Advisory Committee recommends mirabegron(Astellas)for treatment of Overactive Bladder - 08-Apr-2012

Astellas Pharma Inc. has announced that the Reproductive Health Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) voted that the overall risk/benefit assessment supports approval of mirabegron (YM178) for the treatment of Overactive Bladder (OAB) (Yes: 7, No: 4, Abstain: 1).

Related News

NICE recommends Betmiga (Astellas) for patients with Overactive Bladder

New studies support the benefits of Betmiga/Myrbetriq (Astellas) for treating Overactive Bladder

FDA approves Botox (Allergan) as a treatment for Overactive Bladder

EU approves Betmiga (Astellas) for the treatment of Overactive Bladder

Positive data from Phase II trial of Tolenix (TheraVida) for treatment of Overactive Bladder

Botox (Allergan) approved in Ireland for treating Overactive Bladder, the first step towards EU-wide approval

CHMP recommends Betmiga (Astellas) for patients with Overactive Bladder

Botox (Allergan) approved by MHRA in UK for Urinary Incontinence

Related Urological and Kidney Diseases Information

View all

Urological and Kidney Diseases Clinical Guidelines

Anaemia management in chronic kidney disease

NICE

Faecal incontinence: the management of faecal incontinence in adults

NICE
View all

Urological and Kidney Diseases Clinical Trials

The Pharmacokinetics of MK-7145 Following Single Dose Administration in Participants With Moderate Renal Insufficiency (MK-7145-018)

Clinicaltrials.gov 11 April 2013

Multi-Center Randomized Clinical Trial Irreversible Electroporation for the Ablation of Localized Prostate Cancer

Clinicaltrials.gov 08 April 2013
View all

Urological and Kidney Diseases Medical Journal Abstracts

Relationship Between Predictors of the Risk of Clinical Progression of Benign Prostatic Hyperplasia and Metabolic Syndrome in Men With Moderate to Severe Lower Urinary Tract Symptoms

Urology 19 April 2013

Acute Renal Failure Caused by Bilateral Ureteral Herniation Through the Sciatic Foramen

Urology 19 April 2013
View all

Urological and Kidney Diseases Medical Apps

Kidney eGFR Estimator for iPad

£1.49

UTI - Urinary Tract Infection

Free

Related Urological and Kidney Diseases Drugs

Back to top
View all

Latest News

Takeda acquires vaccine maker Inviragen

10 May 2015

Takeda Pharmaceutical Company Limited and Inviragen, Inc. jointly announced that Takeda, its wholly owned subsidiary Takeda America...

Read full article

FreeStyle InsuLinx Blood Glucose Monitoring System (Abbott) is recalled in the USA

22 May 2013

The Freestyle Insulinx Blood Glucose Monitoring System has been recalled by Abbott Diabetes Care in the United States. The FDA has assigned...

Read full article

Genous stent (Orbus Neich) has lower restenosis rate than bare metal stents in ACS treatment

22 May 2013

OrbusNeich announced that the company's Genous Stent is associated with a significantly lower rate of binary restenosis compared to bare...

Read full article